| Biopharm Stock Review; Scientific Advice overshadows Keryx's Wider Q1 Loss - Beacon Equity Research |
|
|
Beacon Equity Research Subsequently, Keryx believes that it will not need to conduct any additional clinical trials with Zerenex in order to obtain European approval in the dialysis setting. The company Friday reported a net loss of $6.4 million or $0.10 per share, ... Keryx Gets Positive Scientific Advice From EMA For Zerenex In Hyperphosphatemia RTT News Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European |